Curcumin treatment alters ERK-1/2 signaling in vitro and inhibits nasopharyngeal carcinoma proliferation in mouse xenografts

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 1, 2014, Pages 108-114

  Xie, Yi Qiang ^a   Wu, Xian Bo ^b   Tang, Song Qi ^b  

^a HAINAN MEDICAL UNIVERSITY   (China)

^b CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Curcumin; ERK1 2 signaling pathway; Matrix metalloproteinases; Nasopharyngeal carcinoma; Proliferation

Indexed keywords

EID: 84892604628     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Asher GN and Spelman K. Clinical utility of curcumin extract. Altern Ther Health Med 2013; 19: 20-22.
2. Choudhuri T, Pal S, Agwarwal ML, Das T and Sa G. Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett 2002; 512: 334-340.
3. Menon LG, Kuttan R and Kuttan G. Anti-metastatic activity of curcumin and catechin. Cancer Lett 1999; 141: 159-165.
4. Chen HW, Yu SL, Chen JJ, Li HN, Lin YC, Yao PL, Chou HY, Chien CT, Chen WJ, Lee YT and Yang PC. Anti-invasive gene expression profile of curcumin in lung adenocarcinoma based on a high throughput microarray analysis. Mol Pharmacol 2004; 65: 99-110.
5. Gupta SC, Kismali G and Aggarwal BB. Curcumin, a component of turmeric: from farm to pharmacy. Biofactors 2013; 39: 2-13.
6. Shehzad A, Lee J and Lee YS. Curcumin in various cancers. Biofactors 2013; 39: 56-68.
7. Kunnumakkara AB, Anand P and Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269: 199-225.
8. Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, Priyadarsini IK and Aggarwal BB. Multi targeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep 2011; 28: 1937-1955.
9. Shehzad A and Lee YS. Molecular mechanisms of curcumin action: signal transduction. Biofactors 2013; 39: 27-36.
10. Kim EK and Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010; 1802: 396-405.
11. Blüthgen N and Legewie S. Systems analysis of MAPK signal transduction. Essays Biochem 2008; 45: 95-107.
12. Kim EK and Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010; 1802: 396-405.
13. Seger R and Krebs EG. The MAPK signaling cascade. FASEB J 1995; 9: 726-735.
14. Cho HS, Chang SH, Chung YS, Shin JY, Park SJ, Lee ES, Hwang SK, Kwon JT, Tehrani AM, Woo M, Noh MS, Hanifah H, Jin H, Xu CX and Cho MH. Synergistic effect of ERK inhibition on tetrandrine-induced apoptosis in A549 human lung carcinoma cells. J Vet Sci 2009; 10: 23-28.
15. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003; 3: 489-501.
16. Shuman Moss LA, Jensen-Taubman S and Stetler-Stevenson WG. Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am J Pathol 2012; 181: 1895-1899.
17. Subramaniam D, Ponnurangam S, Ramamoorthy P, Standing D, Battafarano RJ, Anant S and Sharma P. Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. PLoS One 2012; 7: e30590.
18. Chou J, Lin YC, Kim J, You L, Xu Z, He B and Jablons DM. Nasopharyngeal carcinoma-review of the molecular mechanisms of tumorigenesis. Head Neck 2008; 30: 946-963.
19. Cao Y, DePinho RA, Ernst M and Vousden K. Cancer research: past, present and future. Nat Rev Cancer 2011; 11: 749-754.
20. Jia WH and Qin HD. Non-viral environmental risk factors for nasopharyngeal carcinoma: A systematic review. Semin Cancer Biol 2012; 22: 117-126.
21. Hildesheim A and Wang CP. Genetic predisposition factors and nasopharyngeal carcinoma risk: A review of epidemiological association studies, 2000-2011: Rosetta stone for NPC: Genetics, viral infection, and other environmental factors. Semin Cancer Biol 2012; 22: 107-116.
22. Tao Y, Bidault F, Bosq J and Bourhis J. Distant metastasis of undifferentiated carcinoma of nasopharyngeal type. Onkologie 2008; 31: 574-575.
23. Mccubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM and Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284.
24. Urbanski SJ, Edwards DR, Maitland A, Leco KJ, Watson A and Kossakowska AE. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 1992; 66: 1188-1194.
25. Zhang D, Bar Eli M, Meloche S and Brodt P. Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J Biol Chem 2004; 279: 19683-19690.